Skip to main content
Erschienen in: Digestive Diseases and Sciences 1/2010

01.01.2010 | Original Article

The Discrepancy Between Genetic Polymorphism of p53 Codon 72 and the Expression of p53 Protein in Helicobacter pylori-Associated Gastric Cancer in Korea

verfasst von: Nayoung Kim, Sung-Il Cho, Hye Seung Lee, Ji Hyun Park, Jee Hyun Kim, Joo Sung Kim, Hyun Chae Jung, In Sung Song

Erschienen in: Digestive Diseases and Sciences | Ausgabe 1/2010

Einloggen, um Zugang zu erhalten

Abstract

The p53 gene has been referred to as ‘the guardian of the genome’ because it controls apoptosis and cell cycle arrest. The purpose of this study was to evaluate the association of p53 codon 72 genetic polymorphism and the p53 immunohistochemistry with Helicobacter pylori-associated gastroduodenal diseases, including gastric cancer. This study included 1,852 subjects: controls and patients with gastric cancer, dysplasia, benign gastric ulcers, and duodenal ulcers (DU). Biallelic polymorphism was genotyped by restriction fragment length polymorphism. Immunohistochemical analysis for the detection of mutant type p53 expression was performed. The frequency of the Pro/Pro allele of the p53 codon 72 was higher in the patients with H. pylori-positive dysplasia than in controls (OR: 2.3, 95% CI: 1.3–4.3), but it was less frequent among patients with a H. pylori-positive DU (OR: 0.5, 95% CI: 0.3–0.8). However, there was no significant association with gastric cancer, including the location, stage, or histological type of gastric cancer. Expression of a mutant type of p53 protein was detected in 6.3% of dysplastic tissues and 26.5% of cancerous tissues compared 0% in the controls. Positive expression was higher in the intestinal type of cancer (34.9%) than in the diffuse type (15.0%; P = 0.001). These results suggest that genetic polymorphism of p53 codon 72 played a role in the determination of H. pylori-associated gastroduodenal diseases, but p53 immunostaining did not correlate with those of the p53 genetic polymorphism analysis.
Literatur
1.
Zurück zum Zitat Levine AJ. The p53 tumor suppressor gene and product. Cancer Surv. 1992;12:59–79.PubMed Levine AJ. The p53 tumor suppressor gene and product. Cancer Surv. 1992;12:59–79.PubMed
11.
Zurück zum Zitat Storey A, Thomas M, Kalita A, et al. Role of a p53 polymorphism in the development of human papilloma virus-associated cancer. Nature. 1998;393:229–234. doi:10.1038/30400.CrossRefPubMed Storey A, Thomas M, Kalita A, et al. Role of a p53 polymorphism in the development of human papilloma virus-associated cancer. Nature. 1998;393:229–234. doi:10.​1038/​30400.CrossRefPubMed
12.
13.
17.
Zurück zum Zitat Lauren P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta Pathol Microbiol Scand. 1965;64:31–49.PubMed Lauren P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta Pathol Microbiol Scand. 1965;64:31–49.PubMed
19.
Zurück zum Zitat Correa P. Human gastric carcinogenesis: a multistep and multifactorial process. Cancer Res. 1992;52:6735–6740.PubMed Correa P. Human gastric carcinogenesis: a multistep and multifactorial process. Cancer Res. 1992;52:6735–6740.PubMed
20.
Zurück zum Zitat Perez-Perez GI, Bosques-Padilla FJ, Crosatti ML, Tijerina-Menchaca R, Garza-Gonzalez E. Role of p53 codon 72 polymorphism in the risk of development of distal gastric cancer. Scand J Gastroenterol. 2005;40:56–60. doi:10.1080/00365520410009456.CrossRefPubMed Perez-Perez GI, Bosques-Padilla FJ, Crosatti ML, Tijerina-Menchaca R, Garza-Gonzalez E. Role of p53 codon 72 polymorphism in the risk of development of distal gastric cancer. Scand J Gastroenterol. 2005;40:56–60. doi:10.​1080/​0036552041000945​6.CrossRefPubMed
21.
Zurück zum Zitat Shen H, Solari A, Wang X, et al. p53 codon 72 polymorphism and risk of gastric cancer in a Chinese population. Oncol Rep. 2004;11:1115–1120.PubMed Shen H, Solari A, Wang X, et al. p53 codon 72 polymorphism and risk of gastric cancer in a Chinese population. Oncol Rep. 2004;11:1115–1120.PubMed
25.
Zurück zum Zitat Hiyama T, Tanaka S, Kitadai Y, et al. p53 codon 72 polymorphism in gastric cancer susceptibility in patients with Helicobacter pylori-associated chronic gastritis. Int J Cancer. 2002;100:304–308. doi:10.1002/ijc.10483.CrossRefPubMed Hiyama T, Tanaka S, Kitadai Y, et al. p53 codon 72 polymorphism in gastric cancer susceptibility in patients with Helicobacter pylori-associated chronic gastritis. Int J Cancer. 2002;100:304–308. doi:10.​1002/​ijc.​10483.CrossRefPubMed
27.
Zurück zum Zitat Cover TL, Blaser MJ. Helicobacter pylori infection, a paradigm for chronic mucosal inflammation: pathogenesis and implications for eradication and prevention. Adv Intern Med. 1996;41:85–117.PubMed Cover TL, Blaser MJ. Helicobacter pylori infection, a paradigm for chronic mucosal inflammation: pathogenesis and implications for eradication and prevention. Adv Intern Med. 1996;41:85–117.PubMed
28.
Zurück zum Zitat Dunn BE, Cohen H, Blaser MJ. Helicobacter pylori. Clin Microbiol Rev. 1997;10:720–741.PubMed Dunn BE, Cohen H, Blaser MJ. Helicobacter pylori. Clin Microbiol Rev. 1997;10:720–741.PubMed
29.
Zurück zum Zitat Labigne A, de Reuse H. Determinants of Helicobacter pylori pathogenicity. Infect Agents Dis. 1996;5:191–202.PubMed Labigne A, de Reuse H. Determinants of Helicobacter pylori pathogenicity. Infect Agents Dis. 1996;5:191–202.PubMed
30.
Zurück zum Zitat Mobley HL. Helicobacter pylori factors associated with disease development. Gastroenterology. 1997;113(6):S21–S28.PubMed Mobley HL. Helicobacter pylori factors associated with disease development. Gastroenterology. 1997;113(6):S21–S28.PubMed
31.
Zurück zum Zitat Graham DY. Campylobacter pylori and peptic ulcer disease. Gastroenterology. 1989;96(2 pt 2 Suppl):615–625.PubMed Graham DY. Campylobacter pylori and peptic ulcer disease. Gastroenterology. 1989;96(2 pt 2 Suppl):615–625.PubMed
32.
Zurück zum Zitat Lee A, Dixon MF, Danon SJ, et al. Local acid production and Helicobacter pylori: a unifying hypothesis of gastroduodenal disease. Eur J Gastroenterol Hepatol. 1995;7:461–465.PubMed Lee A, Dixon MF, Danon SJ, et al. Local acid production and Helicobacter pylori: a unifying hypothesis of gastroduodenal disease. Eur J Gastroenterol Hepatol. 1995;7:461–465.PubMed
35.
Zurück zum Zitat Mastumoto Y, Marusawa H, Kinoshita K, et al. Helicobacter pylori infection triggers aberrant expression of activation-induced cytidine deaminase in gastric epithelium. Nat Med. 2007;13:470–476. doi:10.1038/nm1566.CrossRef Mastumoto Y, Marusawa H, Kinoshita K, et al. Helicobacter pylori infection triggers aberrant expression of activation-induced cytidine deaminase in gastric epithelium. Nat Med. 2007;13:470–476. doi:10.​1038/​nm1566.CrossRef
36.
Zurück zum Zitat Gabbert HE, Muller W, Schneiders A, Meier S, Hommel G. The relationship of p53 expression to the prognosis of 418 patients with gastric carcinoma. Cancer. 1995;76:720–726. doi:10.1002/1097-0142(19950901)76:5<720::AID-CNCR2820760503>3.0.CO;2-E.CrossRefPubMed Gabbert HE, Muller W, Schneiders A, Meier S, Hommel G. The relationship of p53 expression to the prognosis of 418 patients with gastric carcinoma. Cancer. 1995;76:720–726. doi:10.1002/1097-0142(19950901)76:5<720::AID-CNCR2820760503>3.0.CO;2-E.CrossRefPubMed
40.
41.
Zurück zum Zitat Loffeld RJ, Stobberingh E, Flendrig JA, Arends JW. Helicobacter pylori in gastric biopsy specimens. Comparison of culture, modified Giemsa stain, and immunohistochemistry. A retrospective study. J Pathol. 1991;165:69–73. doi:10.1002/path.1711650111.CrossRefPubMed Loffeld RJ, Stobberingh E, Flendrig JA, Arends JW. Helicobacter pylori in gastric biopsy specimens. Comparison of culture, modified Giemsa stain, and immunohistochemistry. A retrospective study. J Pathol. 1991;165:69–73. doi:10.​1002/​path.​1711650111.CrossRefPubMed
42.
Zurück zum Zitat Dixon MF, Genta RM, Yardley JH, Correa P. The participants on the International workshop on the Histopathology of Gastritis, Houston 1994. Classification and grading of gastritis: the Updated Sydney System. Am J Surg Pathol. 1996;20:1161–1181. doi:10.1097/00000478-199610000-00001.CrossRefPubMed Dixon MF, Genta RM, Yardley JH, Correa P. The participants on the International workshop on the Histopathology of Gastritis, Houston 1994. Classification and grading of gastritis: the Updated Sydney System. Am J Surg Pathol. 1996;20:1161–1181. doi:10.​1097/​00000478-199610000-00001.CrossRefPubMed
44.
Zurück zum Zitat Thomas M, Kalita A, Labrecque S, Pim D, Banks L, Matlashewski G. Two polymorphic variants of wild-type p53 differ biochemically and biologically. Mol Cell Biol. 1999;19:1092–1100.PubMed Thomas M, Kalita A, Labrecque S, Pim D, Banks L, Matlashewski G. Two polymorphic variants of wild-type p53 differ biochemically and biologically. Mol Cell Biol. 1999;19:1092–1100.PubMed
46.
Zurück zum Zitat Kim JM, Lee OY, Lee CG, et al. p53 codon 72 and 16-bp duplication polymorphisms of gastric cancer in Koreans. Korean J Gastroenterol. 2007;50:292–298.PubMed Kim JM, Lee OY, Lee CG, et al. p53 codon 72 and 16-bp duplication polymorphisms of gastric cancer in Koreans. Korean J Gastroenterol. 2007;50:292–298.PubMed
48.
Zurück zum Zitat Hinds PW, Finlay CA, Quartin RS, et al. Mutant p53 DNA clones from human colon carcinomas cooperate with ras in transforming primary rat cells: a comparison of the ‘hot’ spot mutant phenotypes. Cell Growth Differ. 1990;1:571–580.PubMed Hinds PW, Finlay CA, Quartin RS, et al. Mutant p53 DNA clones from human colon carcinomas cooperate with ras in transforming primary rat cells: a comparison of the ‘hot’ spot mutant phenotypes. Cell Growth Differ. 1990;1:571–580.PubMed
52.
Zurück zum Zitat Joypaul BV, Newman EL, Hopwood D, et al. Expression of p53 protein in normal, dysplastic and malignant gastric mucosa: an immunohistochemical study. J Pathol. 1993;170:279–283.CrossRefPubMed Joypaul BV, Newman EL, Hopwood D, et al. Expression of p53 protein in normal, dysplastic and malignant gastric mucosa: an immunohistochemical study. J Pathol. 1993;170:279–283.CrossRefPubMed
54.
Zurück zum Zitat Hamelin R, Flejou JF, Muzeau F, et al. Tp53 gene mutations and P53 protein immunoreactivity in malignant and premalignant Barretts-esophagus. Gastroenterology. 1994;107:1012–1018.PubMed Hamelin R, Flejou JF, Muzeau F, et al. Tp53 gene mutations and P53 protein immunoreactivity in malignant and premalignant Barretts-esophagus. Gastroenterology. 1994;107:1012–1018.PubMed
55.
Zurück zum Zitat Coggi G, Bosari S, Roncalli M, et al. p53 protein accumulation and p53 gene mutation in esophageal carcinoma—a molecular and immunochemical study with clinicopathologic correlations. Cancer. 1997;79:425–432. doi:10.1002/(SICI)1097-0142(19970201)79:3<425::AID-CNCR1>3.0.CO;2-H.CrossRefPubMed Coggi G, Bosari S, Roncalli M, et al. p53 protein accumulation and p53 gene mutation in esophageal carcinoma—a molecular and immunochemical study with clinicopathologic correlations. Cancer. 1997;79:425–432. doi:10.1002/(SICI)1097-0142(19970201)79:3<425::AID-CNCR1>3.0.CO;2-H.CrossRefPubMed
57.
Zurück zum Zitat Moore JH, Lesser EJ, Erdody DH, Matale RB, Orringer MB, Beer DG. Intestinal differentiation and p53 gene alterations in Barrett's-esophagus and esophageal adenocarcinoma. Int J Cancer. 1994;56:487–493. doi:10.1002/ijc.2910560406.CrossRefPubMed Moore JH, Lesser EJ, Erdody DH, Matale RB, Orringer MB, Beer DG. Intestinal differentiation and p53 gene alterations in Barrett's-esophagus and esophageal adenocarcinoma. Int J Cancer. 1994;56:487–493. doi:10.​1002/​ijc.​2910560406.CrossRefPubMed
58.
Zurück zum Zitat Munro AJ, Lain S, Lane DP. P53 abnormalities and outcomes in colorectal cancer: a systemic review. Br J Cancer. 2005;92:434–444. Munro AJ, Lain S, Lane DP. P53 abnormalities and outcomes in colorectal cancer: a systemic review. Br J Cancer. 2005;92:434–444.
Metadaten
Titel
The Discrepancy Between Genetic Polymorphism of p53 Codon 72 and the Expression of p53 Protein in Helicobacter pylori-Associated Gastric Cancer in Korea
verfasst von
Nayoung Kim
Sung-Il Cho
Hye Seung Lee
Ji Hyun Park
Jee Hyun Kim
Joo Sung Kim
Hyun Chae Jung
In Sung Song
Publikationsdatum
01.01.2010
Verlag
Springer US
Erschienen in
Digestive Diseases and Sciences / Ausgabe 1/2010
Print ISSN: 0163-2116
Elektronische ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-008-0688-x

Weitere Artikel der Ausgabe 1/2010

Digestive Diseases and Sciences 1/2010 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Reizdarmsyndrom: Diäten wirksamer als Medikamente

29.04.2024 Reizdarmsyndrom Nachrichten

Bei Reizdarmsyndrom scheinen Diäten, wie etwa die FODMAP-arme oder die kohlenhydratreduzierte Ernährung, effektiver als eine medikamentöse Therapie zu sein. Das hat eine Studie aus Schweden ergeben, die die drei Therapieoptionen im direkten Vergleich analysierte.

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.